INTRODUCTION
Gastrointestinal tract (GIT) involvement in systemic sclerosis (scleroderma, SSc) is the most common internal complication of this autoimmune disease characterized by progressive vasculopathy and fibrosis [1] . Although the pathogenesis of SSc is not well understood, it has been proposed that akin to the cutaneous manifestations of this disease, an early vascular lesion (vasculopathy) results in altered intestinal permeability, which is followed by neural dysfunction, fibrosis, and loss of function [2] . Although circulating autoantibodies to my enteric neurons are reported in SSc [3, 4] , it is unclear whether these autoantibodies are responsible for or a result of GIT dysfunction. Regardless of its cause, progressive GIT vasculopathy and fibrosis results into bothersome symptoms including esophageal reflux, bloating, distention, constipation, diarrhea, and fecal spoilage. The symptoms of GIT dysfunction are challenging for the physician to assess because it may be the result of organ damage or secondary effects of therapeutics used for other disease manifestations, or poor motility, such as small intestine bacterial overgrowth. As such, understanding the cause of GIT symptoms and measuring response of therapeutics requires a combination of patientreported outcomes (PROs) and imaging modalities. This review discusses tools for measuring response in the GIT in SSc in clinical care and in clinical trials.
There are various tools available to assess the presence and severity of GIT involvement in SSc (Table 1 ). In general, presence of GIT-specific symptoms and abnormal finding on an objective test makes a diagnosis of GIT involvement. However, there are few data available in SSc that longitudinally assess response to therapy in SSc-associated GIT involvement.
UCLA Scleroderma Clinical Trial Consortium GIT 2.0
The UCLA Scleroderma Clinical Trial Consortium GIT 2.0 (UCLA SCTC 2.0) [5, 6] includes 34 items and 7 multitier scales (reflux, distention/bloating, diarrhea, fecal spoilage, constipation, emotional well being, and social functioning) and a total GIT score to assess health-related quality of life (HRQOL) and GIT symptoms severity in SSc. All scales are scored from 0.00 (better HRQOL) to 3.00 (worse HRQOL) except the diarrhea and constipation (range from 0.00 to 2.00 and 0.00 to 2.50, respectively). The UCLA GIT 2.0 provides a total score of GIT severity and calculated by summation of all scales (except constipation) and ranges from 0.00 to 2.83. The GIT 2.0 takes 6-8 minutes to complete and was found to have acceptable feasibility, reliability (test-retest and internal consistency), and validity in different observational studies [5,7-12,13,14 & ]. The severity for scales was calculated using three anchors ['In the past 1 week, how severe were your gastrointestinal, gut, symptoms) overall/ upper/lower symptoms?'] with responses ranging from 'No gut symptoms' to 'Very severe' symptoms. These were assessed using original published data and data collected in a National Scleroderma Foundation online survey ( Table 2 ). The patients have been classified as having 'none-to-mild' symptoms, 'moderate' symptoms, and 'severe-to-very severe' symptoms.
UCLA GIT 2.0 has been assessed in longitudinal studies and minimally important differences have been published [5] . In an open-label study, 10 consecutive patients with SSc and a moderateto-severe distention/bloating score but otherwise stable organ disease not requiring any medication adjustment for their SSc. Subjects completed the UCLA SCTC GIT 2.0 assessment at baseline. Subjects were treated with daily probiotics and significant improvements were noted in the total score and the scale of reflux, bloating/distention, and emotional well being scales after 2 months of daily probiotic use [15] .
KEY POINTS
GIT is a common cause of morbidity and has negative impact on quality of life in SSc.
There is dearth of clinical trials in SSc-GIT because of lack of feasible outcome measures.
Recent evidence supports feasibility, reliability, and validity of UCLA SCTC GIT 2.0 in SSc-GIT as an outcome measure.
Recommendations are provided to validate outcome measures in associated with SSc GERD, gastro paresis, small bowel bacterial overgrowth, constipation, and rectal incontinence. 
Malnutrition universal screening tool
Malnutrition is common in SSc and may be associated with progressive GIT involvement [16, 17] . All SSc patients should be screened for malnutrition, but this may prove challenging, as malnutrition may be multifactorial in origin and not reflective in simple markers such as serum albumin [18, 19] . The Malnutrition Universal Screening Tool is a fivestep screening tool designed to identify patients at risk for malnutrition across the whole range of healthcare settings that has successfully detected malnutrition in SSc [20] [21] [22] . However, although this tool is helpful for identifying its severity and facilitating a multidisciplinary approach for the management of malnutrition, it does not adequately assess the symptomatology contributing to its occurrence.
Subjective Global Assessment
Subjective Global Assessment (SGA) is an assessment tool that uses aspects of the history (including, weight change, dietary intake, gastrointestinal symptoms, functionality) and physical examination (including wasting, edema, and ascites) to classify nutritional status [20, 23] . In one small study [20] of SSc, the spoilage, social function and emotional subscores on the GIT 2.0 were associated with SGA nutritional status. It is feasible in the clinical setting to supplement the GIT 2.0 for assessing nutritional status, and capture aspects of loss of subcutaneous tissue, muscle wasting, and weight loss. However, it does not correlate with disease duration and may not be the best single tool for measuring the response of the GIT in SSc [20] .
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IMAGING MODALITIES
This section discusses the imaging modalities used to assess mucosal involvement and motility in patients with GIT disorders.
Esophageal and stomach
The choice of an imaging modality in assessment of SSc GIT disease may be assisted by the use of a PRO, which quantifies severity of symptoms or response to therapeutics. However, esophageal manifestations of SSc may not always be symptomatic [25] . Nonetheless, early diagnosis of esophageal involvement remains important, as a delay may increase the risk of complications, such as Barrett's or interstitial lung disease [2, 26] . Diagnostic tools used to identify esophageal disorder in SSc may include modified barium swallow study (MBSS), manometry, impedance, endoscopy, and endoscopic ultrasound (EUS). Once identified, response to therapeutics may be identified on repeat imaging. An MBSS can clarify abnormalities of both oropharyngeal and esophageal swallow function. As such, the functional interrelationship between abnormalities of oropharyngeal and esophageal swallowing as well as impaired clearance of the esophagus can be identified with this test [27] . MBSS is usually the first test ordered for evaluation of dysphagia. Although it does not characterize refluxate and is not sufficiently sensitive to determine response to reflux treatment, it is helpful for identification of aspiration and stricture [28] . Reflux may occur because of abnormalities in the relaxation of the lower esophageal sphincter, inhibition of the diaphragmatic crural sling, or change in the positive pressure gradient present between the stomach and the gastroesophageal junction [29] .
Esophageal manometry allows the study of esophageal motility by measuring pressure profiles in the esophagus. The recent development of high-resolution esophageal manometry has further enhanced the ability to study motility in much greater detail by providing pressure measurements at more levels along the esophagus [30] . The most significant limitation of pH-metry is its poor capacity to detect episodes of alkaline reflux; it cannot determine the characteristics of the refluxate, the height reached by the refluxate in the esophagus, or the mechanism of its clearance [31] . Nonetheless, the use of manometry in addition to 24-h combined pH-impedance monitoring may reveal esophageal motility disorders that can predispose to chronic respiratory symptoms and allow detection of reflux regardless of pH [32, 33] .
Endoscopy can be used to evaluate the condition of the esophagus in SSc and to evaluate for erosive lesions, gastric antral vascular ectasia (GAVE; 'watermelon stomach') and can monitor the clinical course of Barrett's esophagus. EUS can accurately demonstrate the layers of the esophageal wall [34] . Capsule endoscopy may also be used to evaluate the esophagus, small bowel, and colon [35] , with possible identification of occult gastrointestinal bleeding from GAVE as its most important indication in SSc.
Computed tomography (CT) and MRI may have features of SSc, such as dilation of the esophagus, but are not diagnostic [36] . Lastly [18] , fluorodeoxyglucose-positron emission tomography provides robust and reproducible data for early metabolic response assessment in various malignancies [37] ; it has not yet been used for assessment of GIT disease in SSc.
Small bowel
The entire small bowel can be visualized in a noninvasive manner by capsule endoscopy, but both visualization and therapeutic management can be performed with deep enteroscopy (ileocolonoscopy) techniques, including balloon-assisted and spiral enteroscopy [38] . CT enterography is another modality for the evaluation of small bowel disease, which has the potential additional advantages of detecting extraluminal complications, but is not the standard of care in SSc [39] .
Large bowel and rectum
Endoscopy directly visualizes the large bowel and rectum, but it does not provide diagnostic motility information. Plain radiograph, rectal barium study, and CT may be used to rule out large bowel obstruction as a complication of SSc [40] . Defecography is helpful to evaluate the anorectal area. In this procedure, a radiopaque substance, which is the consistency of normal stools, is introduced into the rectum and the patient is then seated on a specially designed seat, which measures movements induced by evacuation of the rectum [41] . In the setting of SSc, this procedure can be used to evaluate rectal outlet obstruction (obstructed defecation) symptoms, suspected conditions such as internal rectal intussusception, pelvic floor dysynergia, rectocele, or sigmoidocele. Another possible complication of SSc, pneumatosis intestinalis is characterized by the appearance of intramural clusters of gas in the small and large bowel wall on X-ray or CT and often is accompanied by free air in the peritoneal cavity [42] .
RECOMMENDATIONS FOR VALIDATING OUTCOME MEASURES IN SYSTEMIC SCLEROSIS -GASTROINTESTINAL TRACT INVOLVEMENT
These recommendations are based on the SCTC GI Working Group meeting at the last Annual American College of Rheumatology meeting held in November 2012 at Washington D.C. There are separate ongoing efforts to develop recommendations for clinical trials in SSc and will be published elsewhere. For the each of the symptoms below, the data should be evaluated for feasibility, reliability (including test-retest and internal consistency), and validity (including sensitivity to change) [11, 12] . A feasible measure is accessible, easily interpretable, and associated with low cost. Reliability (precision) is the extent to which a measure yields the same score each time it is administered if the underlying health condition has not changed. A reliability coefficient of 0.90 or higher (means that 90% of the score is accurate while the remaining 10% denotes error) is considered satisfactory for individual comparisons and 0.70 or higher is considered satisfactory for group comparisons. Validity is the extent to which the score a health measure yields accurately reflects the health concept and includes face (sensible), content (comprehensive), construct (measures or correlates with a theorized health construct), and criterion validity (predicts or correlates with 'gold standard'). Sensitivity to change, an aspect of construct validity, assesses if an instrument score changes in the right direction when underlying health construct changes; the ability of an instrument to detect clinically important change is crucial to their usefulness as an outcome measure in a clinical trial.
The outcome measures are chosen based on review of GIT literature and expert opinion. The group agreed on further evaluating outcome measures in patients with signs and symptoms of gastroesophageal reflux disease, gastroparesis, small bowel bacterial overgrowth, constipation, and rectal incontinence.
GASTROESOPHAGEAL REFLUX DISEASE
Although heartburn is the most common symptom of gastroesophageal reflux disease (GERD), other symptoms may include odonophagia, mouth ulcers, substernal chest pain, chronic laryngitis, chronic nocturnal cough, and asthma [43] .
Proposed inclusion criteria for GERD involvement are:
(1) Symptoms of GERD present for at least 3 of last 7 days (2) Abnormal 24 pH probe, pH impedance study, barium swallow (showing spontaneous reflux), or upper gastrointestinal endoscopy (3) Plan to initiate GERD-specific therapy (H 2 blockers/proton pump inhibitor) to assess sensitivity to change over time.
Outcome measures administered at baseline and 4 weeks are Reflux Disease Questionnaire [44] , GIT 2.0 [5] , and Quality of Life in Reflux and Dyspepsia (QOLRAD) [45] .
The Reflux Disease questionnaire consists of six symptom items that has a four-point scale (0-3) for both frequency and intensity, 0 ¼ absent symptoms and 3 ¼ present daily or severe symptoms [44] . QOLRAD is a validated scale using 25 items with five dimensions (physical/social functioning, emotional distress, sleep disturbance, diet problems, and vitality). Responses are based upon a sevenpoint Likert scale that is used to assess the amount of patients' distress, with 1 being the most distress. The total score is calculated as a mean of each dimension [45] . The QOLRAD and Reflux Disease Questionnaire have been assessed for reliability and validity in multiple clinical trials [46] [47] [48] [49] [50] .
GASTROPARESIS
Patients with SSc develop clinical symptoms of gastroparesis, including bloating, nausea and vomiting, abdominal pain, and excessive flatulence; these symptoms may contribute to significant weight loss.
Proposed inclusion criteria for gastroparesis are:
(1) Symptoms of distention/ bloating and/or nausea/ vomiting present for at least 3 of last 7 days (2) Abnormal solid phase gastric emptying study (3) Plan to initiate promotility agents to assess sensitivity to change.
Outcome measures administered at baseline and 4 weeks are Gastroparesis Cardinal Symptom Index [51] , and GIT 2.0 [5] .
The Gastroparesis Cardinal Symptom Index is based on postprandial fullness/early satiety (four items), nausea/vomiting (three items), and bloating (two items). All three subscales are given a score from 0 to 5 with the higher scores reflecting greater symptom severity [51] . Reliability and validity have been assessed in multiple trials [52] [53] [54] .
SMALL BOWEL BACTERIAL OVERGROWTH
The symptoms include bloating, nausea, vomiting, abdominal pain, diarrhea (with pale, greasy, voluminous, foul-smelling stools), excessive flatulence, and inability to gain or maintain body weight with good oral intake; the symptoms overlap with that of gastroparesis.
Proposed inclusion criteria for small bowel bacterial overgrowth are:
(1) Symptoms of distention/bloating with or without diarrhea present for at least 3 of last 7 days (2) Abnormal glucose breath test (3) Plan to initiate antibiotics to assess sensitivity to change.
Outcome measures administered at baseline and 4 weeks are: daily rating on Likert scale for abdominal pain, distention, and diarrhea with 0 indicating not at all; 1, hardly; 2, somewhat; 3, moderately; 4, a good deal; 5, a great deal; and 6, a very great deal, and the GIT 2.0 [5] . Daily rating scale was shown to be feasible, valid, and sensitive to change in a recent large RCT [55] .
CONSTIPATION
Colonic contractions are usually reduced or absent in patients with SSc, resulting in prolonged colonic transit [56] and symptoms of constipation.
Proposed inclusion criteria for constipation are:
(1) Symptoms of constipation (having a bowel movement fewer than three times per week with usually hard, dry, small stools and/or painful bowel movement with straining during bowel movement) present for at least 3 of 7 last days (2) Slow transit constipation using Smart Pill or radio-opaque markers (3) Plan to initiate laxatives and/or fibers to assess sensitivity to change.
Outcome measures administered at baseline and 12 weeks are: proportion of three or more complete spontaneous bowel movements (CSBMs) per week and an increase of one or more CSBMs from baseline during at least 9 of the 12 weeks [57] , and GIT 2.0 [5] .
RECTAL INCONTINENCE
The patients present with chronic diarrhea, fecal incontinence, and rectal prolapse.
Proposed inclusion criteria for rectal incontinence are:
(1) Symptoms of bowel incontinence in 3 of last 7 days (2) Abnormal anorectal manometry showing impaired internal sphincter function (3) Plan for intervention such as surgery, sacral nerve stimulation to assess sensitivity to change.
Outcome measures administered at baseline and 12 weeks are: Fecal Incontinence Quality of Life scale [35] , and GIT 2.0 [5] . Fecal incontinence quality of life scale includes 29 items and four multi-item scales (lifestyle, coping/behavior, depression/self perception, embarrassment). All scales are scored from 1-4, with 1 indicating a lower functional status of quality of life. Scales are the mean to all items in the scale [58] . The fecal incontinence quality of life scale has been found to have acceptable reliability and validity in various studies [59] [60] [61] [62] .
CONCLUSION
This review discusses the available modalities to measure response to therapeutics in SSc-GIT. Identification of the cause of GIT symptomatology in SSc can be aided by the use of PROs and malnutrition assessments, which may guide the ordering of imaging.
